News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

How Roche (RHHBY) And Pfizer Inc. (PFE) Are On Different M&A Paths



8/25/2014 6:21:40 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Roche has just announced the acquisition of the U.S. biotech company InterMune for $8.3 billion. The driver for Roche was to gain access to InterMune’s drug, pirfenidone (trade name, Esbriet), which is already approved in Canada and Europe for idiopathic pulmonary fibrosis (IPF). IPF is a deadly lung-scarring disease which affects 50,000 – 70,000 people in the U.S. and 80,000 to 110,000 in Europe. While still under review by U.S. regulatory authorities, Roche’s acquisition signals its belief that pirfenidone will also gain U.S. approval.

Hey, check out all the research scientist jobs. Post your resume today!

Read at Forbes


comments powered by Disqus
Forbes
Pfizer Inc.
Roche
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES